Abstract: The invention provides N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methyl-propyl)oxy]-4-hydroxyphenyl}acetamide furoate or a solvate thereof, pharmaceutical compositions containing the salt or solvate and use of the salt or solvate in therapy.
Abstract: A process is provided for the preparation of a compound of formula (1) wherein R and R? represent optionally substituted hydrocarbyl groups and X represents a hydrocarbyl linking group. The process comprises either the stereoselective reduction of the keto group in a dihydroxy keto precursor followed by selective esterification of a primary hydroxy, or selective esterification of a primary hydroxy of a dihydroxy keto precursor followed by stereoselective reduction of the keto group.
Type:
Application
Filed:
July 23, 2008
Publication date:
November 13, 2008
Applicant:
ASTRAZENECA UK LIMITED
Inventors:
Andrew John Blacker, Christopher David Reeve, Robert Anthony Holt
Abstract: Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
Type:
Application
Filed:
May 17, 2006
Publication date:
November 13, 2008
Applicants:
ARRAY BIOPHARMA, INC., ASTRAZENECA AB
Inventors:
Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hoog Woon Yang, James Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding
Abstract: The invention relates to a group of novel indole compounds of Formula (I): wherein: R1, R2, R4, R6, R6a, R7, R8, R9, R10, and A are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
Type:
Grant
Filed:
August 18, 2003
Date of Patent:
November 11, 2008
Assignee:
AstraZeneca AB
Inventors:
Francis Thomas Boyle, Robert Davies, Zbigniew Matusiak, Michael Wardleworth
Abstract: The invention provides compounds of formula (I) wherein m R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t, and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract: There is provided a combination product comprising; (A) melagatran or a pharmaceutically acceptable derivative thereof; and (B) dexamethasone or a pharmaceutically acceptable derivative there of, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, as well as the use of such a combination product in the treatment of conditions including disseminated intravascular coagulation.
Abstract: The present invention relates to methods of determining activity of flavin adenine dinucleotide (FAD) synthetase, and methods of identifying compounds that modulate the activity of this enzyme.
Abstract: Compounds of formula Ia or Ib wherein P; R1; R2; m; and n are as defined in the application, salts thereof, processed for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.
Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
Type:
Application
Filed:
June 14, 2005
Publication date:
November 6, 2008
Applicant:
AstraZeneca AB
Inventors:
Brian Aquila, Les Dakin, Jayachandran Ezhuthachan, John Lee, Paul Lyne, Timothy Pontz
Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
Abstract: The present invention relates to fusion proteins and their use in enzymatic treatment of Alzheimer's disease patients. Said fusion protein comprises a component that cleaves the amyloid beta (Ab) peptide e.g. neprilysin, insulin degrading enzyme (IDE), another component that modulates the half-life in plasma e.g. the Fc portion of IgG or PEG; and a third component that connects the first two components.
Abstract: Compounds of the formula (I) wherein R1, R2, R3, R4, R5, R6 and p are as defined within and pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
Type:
Grant
Filed:
March 6, 2003
Date of Patent:
November 4, 2008
Assignee:
AstraZeneca AB
Inventors:
Nicholas John Newcombe, Andrew Peter Thomas
Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
Type:
Application
Filed:
October 30, 2007
Publication date:
October 30, 2008
Applicant:
AstraZeneca AB
Inventors:
William McCoull, Martin Packer, James Stewart Scott, Paul Robert Owen Whittamore
Abstract: An adenine compound useful as a medicine represented by the following formula (1): [wherein R1 is halogen atom, optionally substituted alkyl group, optionally substituted aryl group, etc.; X is oxygen atom, sulfur atom, a single bond, etc.; A1 is optionally substituted and optionally saturated 4 to 8 membered heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom, and 0 to 1 sulfur atom; A2 is optionally substituted 6 to 10 cyclic aromatic hydrocarbon group or optionally substituted 5 to 10 membered heterocyclic aromatic group; L1 and L2 are independently, substituted straight or branched alkylene or a single bond, etc.; L3 is optionally substituted straight or branched alkylene, etc.; R2 is hydrogen atom, optionally substituted alkyl group.] or its pharmaceutically acceptable salt.
Type:
Application
Filed:
September 21, 2006
Publication date:
October 30, 2008
Applicants:
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan, AstraZeneca Aktiebolag A Corporation of Sweden
Abstract: There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Type:
Application
Filed:
March 26, 2008
Publication date:
October 30, 2008
Applicant:
ASTRAZENECA AB
Inventors:
Thorsten Nowak, Andrew Peter Thomas, Stuart Charles Purkiss
Abstract: There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents C1-2 alkyl; and n represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required.
Type:
Application
Filed:
August 16, 2007
Publication date:
October 30, 2008
Applicant:
AstraZeneca AB
Inventors:
Matti Ahlqvist, Martin Bohlin, Tord Inghardt, Anita Lundblad, Carl-Gustaf Sigfridsson
Abstract: The invention concerns benzamide compounds of formula (I), wherein R1 is a C-linked pyrazole ring, which is optionally substituted by one or more groups selected from C1-4alkyl, C3-4cycloalkyl, C1-4alkoxy and C3-4cycloalkoxy; or a pharmaceutically acceptable salt or pro-drug form thereof. The invention also concerns processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase (HDAC).
Type:
Application
Filed:
October 17, 2005
Publication date:
October 30, 2008
Applicant:
ASTRAZENECA AB
Inventors:
David Michael Andrews, Elaine Sophie Elizabeth Stokes, Andrew Turner, Michael James Waring
Abstract: Compounds of Formula I wherein R1, D, R2, A and R3 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
Type:
Application
Filed:
May 29, 2006
Publication date:
October 30, 2008
Applicant:
ASTRAZENECA AB
Inventors:
Dean Brown, William Blackwell, Frances M. McLaren, Volker Schnecke, Reed W. Smith, Gary Steelman, Xia Wang, Rebecca Urbanek, Steven Wesolowski
Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described: Formula (I). Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
Type:
Application
Filed:
March 2, 2006
Publication date:
October 30, 2008
Applicant:
ASTRAZENECA AB
Inventors:
Gregory Steven Basarab, Michael Barry Gravestock, Sheila Irene Hauck
Abstract: Processes for the preparation of 4-aminopyrazole and derivatives thereof, such as those of formula (C), which are useful as intermediates in the preparation of pharmaceutical compounds; to certain compounds used in these processes; and to processes for the preparation of said compounds.